Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HCMNASDAQ:MIRMNASDAQ:VECTNASDAQ:XENE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHCMHUTCHMED$13.09-1.6%$14.51$11.51▼$21.50$2.28B0.55101,938 shs64,243 shsMIRMMirum Pharmaceuticals$45.28+2.0%$42.94$23.83▼$54.23$2.24B0.95524,557 shs230,973 shsVECTVectivBio$16.85$16.85$4.25▼$16.98$573.24M0.11N/AN/AXENEXenon Pharmaceuticals$29.57-0.6%$34.19$26.74▼$46.00$2.26B1.21508,722 shs1.15 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHCMHUTCHMED+1.22%-8.90%-10.68%+0.61%-37.85%MIRMMirum Pharmaceuticals-1.94%+7.69%+12.12%-12.45%+78.99%VECTVectivBio0.00%0.00%0.00%0.00%0.00%XENEXenon Pharmaceuticals+0.47%-15.82%-11.06%-24.25%-26.71%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHCMHUTCHMED2.252 of 5 stars3.04.00.00.01.10.01.9MIRMMirum Pharmaceuticals4.1599 of 5 stars3.61.00.04.23.52.50.6VECTVectivBioN/AN/AN/AN/AN/AN/AN/AN/AXENEXenon Pharmaceuticals2.5236 of 5 stars4.51.00.00.02.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHCMHUTCHMED 2.00Hold$19.0045.15% UpsideMIRMMirum Pharmaceuticals 3.17Buy$60.6433.91% UpsideVECTVectivBio 0.00N/AN/AN/AXENEXenon Pharmaceuticals 3.00Buy$54.8285.38% UpsideCurrent Analyst Ratings BreakdownLatest VECT, HCM, XENE, and MIRM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025XENEXenon PharmaceuticalsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$55.005/13/2025MIRMMirum PharmaceuticalsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingStrong-Buy ➝ Strong-Buy5/13/2025HCMHUTCHMEDHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold5/13/2025MIRMMirum PharmaceuticalsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$73.00 ➝ $77.005/13/2025XENEXenon PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$50.00 ➝ $47.005/13/2025XENEXenon PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$58.00 ➝ $55.005/13/2025XENEXenon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$53.00 ➝ $53.005/13/2025XENEXenon PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$55.00 ➝ $55.005/13/2025XENEXenon PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$60.00 ➝ $55.005/9/2025MIRMMirum PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$74.00 ➝ $76.005/7/2025XENEXenon PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$55.00(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHCMHUTCHMED$630.20M3.62$0.53 per share24.51$4.27 per share3.07MIRMMirum Pharmaceuticals$379.25M5.91N/AN/A$5.33 per share8.50VECTVectivBio$27.34M20.97N/AN/AN/A∞XENEXenon Pharmaceuticals$9.43M240.18N/AN/A$14.18 per share2.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHCMHUTCHMED$100.78MN/A0.008.97N/AN/AN/AN/A6/18/2025 (Estimated)MIRMMirum Pharmaceuticals-$163.41M-$1.61N/AN/AN/A-31.69%-41.22%-14.81%N/AVECTVectivBio-$93.74MN/A0.00∞N/AN/AN/AN/AN/AXENEXenon Pharmaceuticals-$182.39M-$3.02N/AN/AN/AN/A-24.69%-23.68%N/ALatest VECT, HCM, XENE, and MIRM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MIRMMirum Pharmaceuticals-$0.35-$0.30+$0.05-$0.30$98.47 million$111.59 million5/12/2025Q1 2025XENEXenon Pharmaceuticals-$0.90-$0.83+$0.07-$0.83$1.64 million$7.50 million2/27/2025Q4 2024XENEXenon Pharmaceuticals-$0.89-$0.84+$0.05-$0.84$0.31 millionN/A2/26/2025Q4 2024MIRMMirum Pharmaceuticals-$0.27-$0.49-$0.22-$0.49$96.64 million$99.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHCMHUTCHMEDN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/AVECTVectivBioN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHCMHUTCHMED0.072.812.68MIRMMirum Pharmaceuticals1.333.343.15VECTVectivBioN/AN/AN/AXENEXenon PharmaceuticalsN/A22.2122.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHCMHUTCHMED8.82%MIRMMirum PharmaceuticalsN/AVECTVectivBioN/AXENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipHCMHUTCHMED3.60%MIRMMirum Pharmaceuticals14.36%VECTVectivBio9.70%XENEXenon Pharmaceuticals5.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHCMHUTCHMED1,760174.32 million168.04 millionNot OptionableMIRMMirum Pharmaceuticals14049.54 million37.03 millionOptionableVECTVectivBio3034.02 millionN/ANo DataXENEXenon Pharmaceuticals21076.59 million72.03 millionOptionableVECT, HCM, XENE, and MIRM HeadlinesRecent News About These CompaniesWhy Xenon Pharmaceuticals Inc. (XENE) Declined on TuesdayMay 15 at 3:41 PM | insidermonkey.comPolarean's Xenon MRI technology to feature in over 30 studies at American Thoracic Society eventsMay 15 at 11:36 AM | proactiveinvestors.co.ukXenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Down on Analyst DowngradeMay 15 at 10:35 AM | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Given "Buy" Rating at HC WainwrightMay 15 at 9:10 AM | marketbeat.comXenon MRI Featured Prominently at ATS 2025 Across Broad Clinical SpectrumMay 15 at 8:49 AM | globenewswire.comXenon Pharmaceuticals' (XENE) Buy Rating Reiterated at Chardan CapitalMay 15 at 8:19 AM | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Price Target Lowered to $55.00 at Needham & Company LLCMay 15 at 8:19 AM | marketbeat.comOrbimed Advisors LLC Has $37.16 Million Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)May 15 at 7:52 AM | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Q1 2025 Earnings Call TranscriptMay 15 at 5:39 AM | msn.comEvercore ISI Group Initiates Coverage of Xenon Pharmaceuticals (XENE) with Outperform RecommendationMay 15 at 5:39 AM | msn.comJanus Henderson Group PLC Boosts Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)May 15 at 5:27 AM | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Price Target Cut to $47.00 by Analysts at Wells Fargo & CompanyMay 15 at 1:49 AM | americanbankingnews.comXenon Pharmaceuticals (NASDAQ:XENE) Announces Earnings ResultsMay 14 at 4:53 PM | marketbeat.comXenon to Present at the 2025 RBC Capital Markets Global Healthcare ConferenceMay 14 at 4:01 PM | globenewswire.comWhy Xenon Pharmaceuticals Inc. (XENE) Declined on TuesdayMay 14 at 8:32 AM | finance.yahoo.comXenon Pharmaceuticals Inc.: Xenon Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13 at 3:28 PM | finanznachrichten.deXenon Pharmaceuticals stock falls on delayed study resultsMay 13 at 3:28 PM | investing.comXenon Pharmaceuticals Inc (XENE) Q1 2025 Earnings Call Highlights: Strong Financial Position ...May 13 at 3:28 PM | finance.yahoo.comXenon Q1 Loss Narrower Than Expected, Pipeline Development in FocusMay 13 at 1:10 PM | zacks.comXenon Pharmaceuticals Inc. (XENE) Q1 2025 Earnings Call TranscriptMay 12 at 11:14 PM | seekingalpha.comXenon Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 12 at 4:01 PM | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVECT, HCM, XENE, and MIRM Company DescriptionsHUTCHMED NASDAQ:HCM$13.09 -0.21 (-1.58%) As of 04:00 PM EasternHUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.Mirum Pharmaceuticals NASDAQ:MIRM$45.28 +0.89 (+2.00%) As of 04:00 PM EasternMirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.VectivBio NASDAQ:VECT$16.85 0.00 (0.00%) As of 05/14/2025VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.Xenon Pharmaceuticals NASDAQ:XENE$29.57 -0.17 (-0.57%) As of 04:00 PM EasternXenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas An Acquisition Just Made Dick's the Most Exciting Stock in Retail Walmart Stock Alert: Big Price Move Expected Soon Broadcom Set to Surge as AI Diffusion Rule Ends Microsoft and OpenAI Just Hit Reset—Here’s Why MSFT Stock Wins Is Bally’s Turnaround a Safe Bet Amid Mixed Investor Sentiment? SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start Intel Makes a Cool Move With Shell, But Will Investors Warm Up? AMD’s AI-Powered Stock Price Rally Just Shifted Gears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
